Loading…

Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial

Background: Pneumococcal diseases among children aged 0.35 ㎍/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs. 90.20%, P97% of the subjects in each group achieved IgG concentrations of ≥0.35 ㎍/mL for all 12 serotypes....

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental pediatrics 2020, Vol.63 (7), p.265-271
Main Authors: Shin, Jonghoon, Teeratakulpisarn, Jamaree, Puthanakit, Thanyawee, Theerawit, Tuangtip, Ryu, Ji Hwa, Shin, Jinhwan, Lee, Seulgi, Lee, Hayoung, An, Kyungjun, Kim, Hun
Format: Article
Language:Korean
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 271
container_issue 7
container_start_page 265
container_title Clinical and experimental pediatrics
container_volume 63
creator Shin, Jonghoon
Teeratakulpisarn, Jamaree
Puthanakit, Thanyawee
Theerawit, Tuangtip
Ryu, Ji Hwa
Shin, Jinhwan
Lee, Seulgi
Lee, Hayoung
An, Kyungjun
Kim, Hun
description Background: Pneumococcal diseases among children aged 0.35 ㎍/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs. 90.20%, P97% of the subjects in each group achieved IgG concentrations of ≥0.35 ㎍/mL for all 12 serotypes. Increased immunogenicity was observed for some serotypes that showed significant intergroup differences after administration of the primary doses but not after the booster dose. We also found no significant intergroup difference in the overall incidence of solicited local adverse events. Furthermore, the overall incidence of solicited systemic adverse events was significantly lower in the GBP411 group than in the comparator vaccine group (79.59% vs. 98.04%; P=0.003). Conclusion: The GBP411 vaccine with a dosing schedule of 2p+1 may be immunogenic and safe for healthy infants.
format article
fullrecord <record><control><sourceid>kisti</sourceid><recordid>TN_cdi_kisti_ndsl_JAKO202026163872364</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JAKO202026163872364</sourcerecordid><originalsourceid>FETCH-kisti_ndsl_JAKO2020261638723643</originalsourceid><addsrcrecordid>eNqNjc9KxDAQh4MguOi-w1w8Bpo22xZvi-zin4MX78s0nZZx08nSpBV9D9_XHHwA-Q3MwDd8vyu1KRtTaWtse6O2MXJXWNuYdrdrN-rneZoWCSMJO05fgNJDxIHyGQZAMKVe0ZMkuAgtU3DBOfTggnwsIyaCFZ1jIWDJM6CkCDhSD7U2BXwSneND1szZGyb-zqAPS-dJd55zFbrEK-msS3PwPuM0M_o7dT2gj7T927fq_nh4f3zSZ46JT9JHf3rZv76VRU5t6qptyqq21X__fgFcJ1Ye</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial</title><source>PubMed (Medline)</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Shin, Jonghoon ; Teeratakulpisarn, Jamaree ; Puthanakit, Thanyawee ; Theerawit, Tuangtip ; Ryu, Ji Hwa ; Shin, Jinhwan ; Lee, Seulgi ; Lee, Hayoung ; An, Kyungjun ; Kim, Hun</creator><creatorcontrib>Shin, Jonghoon ; Teeratakulpisarn, Jamaree ; Puthanakit, Thanyawee ; Theerawit, Tuangtip ; Ryu, Ji Hwa ; Shin, Jinhwan ; Lee, Seulgi ; Lee, Hayoung ; An, Kyungjun ; Kim, Hun</creatorcontrib><description>Background: Pneumococcal diseases among children aged &lt;5 years worldwide are associated with high annual mortality rates. Purpose: This study aimed to evaluate the immunogenicity and safety of GBP411, a 12-valent pneumococcal conjugant vaccine, with a dosing schedule of 2 primary doses plus 1 booster dose (2p+1) in healthy infants. Methods: This randomized active-controlled (Prevnar 13) double-blind phase 2 trial enrolled healthy subjects aged 6-10 weeks. Three serum concentrations of pneumococcal serotype-specific immunoglobulin G (IgG) were evaluated using the pneumococcal serotype-specific pneumonia polysaccharide enzyme-linked immunosorbent assay at 1 month after the primary doses and before and 1 month after the booster dose. The pneumococcal serotype-specific IgG titer was evaluated using a multiplex opsonophagocytic assay in a subset of 15 subjects per group. Results: After administration of the primary doses, the proportion of subjects who achieved pneumococcal serotype-specific IgG concentrations of &gt;0.35 ㎍/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs. 90.20%, P&lt;0.001). However, after administration of the booster dose, &gt;97% of the subjects in each group achieved IgG concentrations of ≥0.35 ㎍/mL for all 12 serotypes. Increased immunogenicity was observed for some serotypes that showed significant intergroup differences after administration of the primary doses but not after the booster dose. We also found no significant intergroup difference in the overall incidence of solicited local adverse events. Furthermore, the overall incidence of solicited systemic adverse events was significantly lower in the GBP411 group than in the comparator vaccine group (79.59% vs. 98.04%; P=0.003). Conclusion: The GBP411 vaccine with a dosing schedule of 2p+1 may be immunogenic and safe for healthy infants.</description><identifier>EISSN: 2713-4148</identifier><language>kor</language><ispartof>Clinical and experimental pediatrics, 2020, Vol.63 (7), p.265-271</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,4024</link.rule.ids></links><search><creatorcontrib>Shin, Jonghoon</creatorcontrib><creatorcontrib>Teeratakulpisarn, Jamaree</creatorcontrib><creatorcontrib>Puthanakit, Thanyawee</creatorcontrib><creatorcontrib>Theerawit, Tuangtip</creatorcontrib><creatorcontrib>Ryu, Ji Hwa</creatorcontrib><creatorcontrib>Shin, Jinhwan</creatorcontrib><creatorcontrib>Lee, Seulgi</creatorcontrib><creatorcontrib>Lee, Hayoung</creatorcontrib><creatorcontrib>An, Kyungjun</creatorcontrib><creatorcontrib>Kim, Hun</creatorcontrib><title>Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial</title><title>Clinical and experimental pediatrics</title><addtitle>Clinical and experimental pediatrics</addtitle><description>Background: Pneumococcal diseases among children aged &lt;5 years worldwide are associated with high annual mortality rates. Purpose: This study aimed to evaluate the immunogenicity and safety of GBP411, a 12-valent pneumococcal conjugant vaccine, with a dosing schedule of 2 primary doses plus 1 booster dose (2p+1) in healthy infants. Methods: This randomized active-controlled (Prevnar 13) double-blind phase 2 trial enrolled healthy subjects aged 6-10 weeks. Three serum concentrations of pneumococcal serotype-specific immunoglobulin G (IgG) were evaluated using the pneumococcal serotype-specific pneumonia polysaccharide enzyme-linked immunosorbent assay at 1 month after the primary doses and before and 1 month after the booster dose. The pneumococcal serotype-specific IgG titer was evaluated using a multiplex opsonophagocytic assay in a subset of 15 subjects per group. Results: After administration of the primary doses, the proportion of subjects who achieved pneumococcal serotype-specific IgG concentrations of &gt;0.35 ㎍/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs. 90.20%, P&lt;0.001). However, after administration of the booster dose, &gt;97% of the subjects in each group achieved IgG concentrations of ≥0.35 ㎍/mL for all 12 serotypes. Increased immunogenicity was observed for some serotypes that showed significant intergroup differences after administration of the primary doses but not after the booster dose. We also found no significant intergroup difference in the overall incidence of solicited local adverse events. Furthermore, the overall incidence of solicited systemic adverse events was significantly lower in the GBP411 group than in the comparator vaccine group (79.59% vs. 98.04%; P=0.003). Conclusion: The GBP411 vaccine with a dosing schedule of 2p+1 may be immunogenic and safe for healthy infants.</description><issn>2713-4148</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNjc9KxDAQh4MguOi-w1w8Bpo22xZvi-zin4MX78s0nZZx08nSpBV9D9_XHHwA-Q3MwDd8vyu1KRtTaWtse6O2MXJXWNuYdrdrN-rneZoWCSMJO05fgNJDxIHyGQZAMKVe0ZMkuAgtU3DBOfTggnwsIyaCFZ1jIWDJM6CkCDhSD7U2BXwSneND1szZGyb-zqAPS-dJd55zFbrEK-msS3PwPuM0M_o7dT2gj7T927fq_nh4f3zSZ46JT9JHf3rZv76VRU5t6qptyqq21X__fgFcJ1Ye</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Shin, Jonghoon</creator><creator>Teeratakulpisarn, Jamaree</creator><creator>Puthanakit, Thanyawee</creator><creator>Theerawit, Tuangtip</creator><creator>Ryu, Ji Hwa</creator><creator>Shin, Jinhwan</creator><creator>Lee, Seulgi</creator><creator>Lee, Hayoung</creator><creator>An, Kyungjun</creator><creator>Kim, Hun</creator><scope>JDI</scope></search><sort><creationdate>2020</creationdate><title>Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial</title><author>Shin, Jonghoon ; Teeratakulpisarn, Jamaree ; Puthanakit, Thanyawee ; Theerawit, Tuangtip ; Ryu, Ji Hwa ; Shin, Jinhwan ; Lee, Seulgi ; Lee, Hayoung ; An, Kyungjun ; Kim, Hun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kisti_ndsl_JAKO2020261638723643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shin, Jonghoon</creatorcontrib><creatorcontrib>Teeratakulpisarn, Jamaree</creatorcontrib><creatorcontrib>Puthanakit, Thanyawee</creatorcontrib><creatorcontrib>Theerawit, Tuangtip</creatorcontrib><creatorcontrib>Ryu, Ji Hwa</creatorcontrib><creatorcontrib>Shin, Jinhwan</creatorcontrib><creatorcontrib>Lee, Seulgi</creatorcontrib><creatorcontrib>Lee, Hayoung</creatorcontrib><creatorcontrib>An, Kyungjun</creatorcontrib><creatorcontrib>Kim, Hun</creatorcontrib><collection>KoreaScience</collection><jtitle>Clinical and experimental pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shin, Jonghoon</au><au>Teeratakulpisarn, Jamaree</au><au>Puthanakit, Thanyawee</au><au>Theerawit, Tuangtip</au><au>Ryu, Ji Hwa</au><au>Shin, Jinhwan</au><au>Lee, Seulgi</au><au>Lee, Hayoung</au><au>An, Kyungjun</au><au>Kim, Hun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial</atitle><jtitle>Clinical and experimental pediatrics</jtitle><addtitle>Clinical and experimental pediatrics</addtitle><date>2020</date><risdate>2020</risdate><volume>63</volume><issue>7</issue><spage>265</spage><epage>271</epage><pages>265-271</pages><eissn>2713-4148</eissn><abstract>Background: Pneumococcal diseases among children aged &lt;5 years worldwide are associated with high annual mortality rates. Purpose: This study aimed to evaluate the immunogenicity and safety of GBP411, a 12-valent pneumococcal conjugant vaccine, with a dosing schedule of 2 primary doses plus 1 booster dose (2p+1) in healthy infants. Methods: This randomized active-controlled (Prevnar 13) double-blind phase 2 trial enrolled healthy subjects aged 6-10 weeks. Three serum concentrations of pneumococcal serotype-specific immunoglobulin G (IgG) were evaluated using the pneumococcal serotype-specific pneumonia polysaccharide enzyme-linked immunosorbent assay at 1 month after the primary doses and before and 1 month after the booster dose. The pneumococcal serotype-specific IgG titer was evaluated using a multiplex opsonophagocytic assay in a subset of 15 subjects per group. Results: After administration of the primary doses, the proportion of subjects who achieved pneumococcal serotype-specific IgG concentrations of &gt;0.35 ㎍/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs. 90.20%, P&lt;0.001). However, after administration of the booster dose, &gt;97% of the subjects in each group achieved IgG concentrations of ≥0.35 ㎍/mL for all 12 serotypes. Increased immunogenicity was observed for some serotypes that showed significant intergroup differences after administration of the primary doses but not after the booster dose. We also found no significant intergroup difference in the overall incidence of solicited local adverse events. Furthermore, the overall incidence of solicited systemic adverse events was significantly lower in the GBP411 group than in the comparator vaccine group (79.59% vs. 98.04%; P=0.003). Conclusion: The GBP411 vaccine with a dosing schedule of 2p+1 may be immunogenic and safe for healthy infants.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 2713-4148
ispartof Clinical and experimental pediatrics, 2020, Vol.63 (7), p.265-271
issn 2713-4148
language kor
recordid cdi_kisti_ndsl_JAKO202026163872364
source PubMed (Medline); Publicly Available Content Database (Proquest) (PQ_SDU_P3)
title Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A56%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kisti&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20safety%20of%20a%2012-valent%20pneumococcal%20conjugate%20vaccine%20in%20infants%20aged%206-10%20weeks:%20a%20randomized%20double-blind%20active-controlled%20trial&rft.jtitle=Clinical%20and%20experimental%20pediatrics&rft.au=Shin,%20Jonghoon&rft.date=2020&rft.volume=63&rft.issue=7&rft.spage=265&rft.epage=271&rft.pages=265-271&rft.eissn=2713-4148&rft_id=info:doi/&rft_dat=%3Ckisti%3EJAKO202026163872364%3C/kisti%3E%3Cgrp_id%3Ecdi_FETCH-kisti_ndsl_JAKO2020261638723643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true